Core Scientific, Inc./tx
CORZ · XNASCIK 1839341fmd_1Z0HNR008N0DSEKA4HHH4JTJVNFinance, Insurance and Real Estate · Finance ServicesTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 60 | 544 | 640 | 502 | 511 | 319 |
| Rental revenue | – | – | 0 | 0 | 24 | 65 |
| Cost of revenue | 51 | 306 | 632 | 379 | 390 | 281 |
| Gross profit | 9 | 239 | 8 | 123 | 121 | 38 |
| Realized investment gains (losses) | – | 0 | – | – | – | – |
| Research and development | 5 | 8 | 27 | 7 | 12 | – |
| Selling, general and administrative | 16 | 65 | 226 | 108 | 114 | 159 |
| Total operating expenses | 22 | 72 | 253 | – | – | – |
| Operating income | (6) | 131 | (2,110) | 9 | (142) | (246) |
| Interest and investment income | – | 0 | – | – | – | – |
| Other non-operating income (expense) | (6) | (68) | (54) | (255) | (1,295) | (42) |
| Income before taxes | (12) | 63 | (2,163) | (246) | (1,437) | (288) |
| Income tax expense | 0 | 16 | (17) | 1 | 1 | 1 |
| Net income from continuing operations | (12) | 47 | (2,146) | (246) | (1,438) | (289) |
| Net income | (12) | 47 | (2,146) | (246) | (1,438) | (289) |
| Net income to common shareholders | (23) | 47 | (2,146) | (246) | (1,245) | (281) |